SSII SS Innovations International (SSII) Insider Trading, Ownership & Congress Trades
Medical Devices · Surgical & medical instruments & apparatus · CIK 0001676163
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
6
13F, latest reported quarter
What the filings say about SSII
Insiders, 180 days
-$100.0K net sold
1 seller · 0% of sales under a 10b5-1 plan
SS Innovations International insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, SS Innovations International, Inc. insiders sold a net $100.0K of stock across 85 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Mar 6, 2026.
- The trade is 0.0% of the 108,520,928 shares held after it.
- No other insider sold within 30 days.
- 6 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chairman and CEO Sudhir Srivastava sold about $100.0K of SSII on Sep 4, 2026, the largest insider sale at the company since 2025; 6 funds added in the latest 13F quarter.Context
- 4 earlier Form 4 trades (code P or S) here by this insider (4 buys), the last on Feb 20, 2025.
- +18.6% median (+47.1% mean) 90-day return after 4 previous buys.
- The trade is 4.7% of the 10,775,485 shares held after it.
- 2 other insiders bought within 30 days.
- 6 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director MOLL FREDERIC H bought about $2.0M of SSII on Mar 6, 2026, the largest insider purchase at the company since 2025; 2 other insiders bought within 30 days and 6 funds added in the latest 13F quarter.Context
- 3 earlier Form 4 trades (code P or S) here by this insider (3 buys), the last on Feb 14, 2025.
- +126.3% median (+87.0% mean) 90-day return after 3 previous buys.
- The trade is 5.6% of the 5,331,902 shares held after it.
- 2 other insiders bought within 30 days.
- 6 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Adams Timothy P. bought about $1.2M of SSII on Mar 6, 2026, the largest insider purchase at the company since 2025; 2 other insiders bought within 30 days and 6 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 0.5% of the 109,851,767 shares held after it.
- 2 other insiders bought within 30 days.
- 6 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chairman and CEO Sudhir Srivastava bought about $2.0M of SSII on Mar 6, 2026, the largest insider purchase at the company since 2025; 2 other insiders bought within 30 days and 6 funds added in the latest 13F quarter.Context
- 61 earlier Form 4 trades (code P or S) here by this insider (61 buys), the last on Apr 17, 2025.
- -5.4% median (-5.2% mean) 90-day return after 30 previous buys.
- The trade is 0.0% of the 8,866,662 shares held after it.
- No other insider bought within 30 days.
- 6 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: COO - Americas Cohen Barry F bought about $890 of SSII on Apr 22, 2025; 6 funds added in the latest 13F quarter.85 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$100.0K over 180 days
-$100.0K over 90 days · -$100.0K of it by a 10%+ holder
more than 56% of Medical Devices
Congress
no House purchase disclosed in the last 12 months
Funds
6 funds bought in last quarter
below 95% of Medical Devices
Revenue
+105.7% year over year
more than 93% of Medical Devices
Margin
-28.5% net margin
below 59% of Medical Devices
Buybacks
no share repurchases reported
Short interest
0.2% of the float short (float per yahoo 2026-10-27) · 1.2 days to cover · settled 2026-10-15
below 91% of Medical Devices
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch SSII
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-74.4%12M
Insider buyInsider sell
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns SSII: institutional holders (13F)
13F holdings, latest reported quarter
833,333 sh
$3.5M
186,297 sh
$773.1K
110,157 sh
$457.2K
102,291 sh
$424.5K
51,208 sh
$212.5K
Congress trades in SSII
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
SSII planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
SSII mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
AlphaCentric Robotics and Automation Fund
$207.5K position · as of 2026-06-30
0.8%
Hood River International Opportunity Fund
$3.5M position · as of 2026-06-30
0.6%
Inspire Small/Mid Cap ETF
$430.7K position · as of 2026-05-31
0.1%
State Street(R) SPDR(R) S&P(R) Emerging Markets Small Cap ETF
$60.3K position · as of 2026-06-30
0.0%
TIFF MULTI-ASSET FUND
$10.0K position · as of 2026-06-30
0.0%
Fidelity Nasdaq Composite Index Fund
$154.8K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows a net $100.0K sold by insiders over 180 days, 6 funds added last quarter. Each figure is a federal filing, dated the day it went public.
SSII financials
Revenue growth
+105.7%
XBRL, annual
Net margin
-28.5%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$52.4M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM SSII
| FY Dec 2025 | $42.5M |
| FY Dec 2024 | $20.6M |
| FY Dec 2023 | $5.9B |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | $13.9M |
| Mar 2026 | $11.1M |
| Dec 2025 | $14.5M |
| Sep 2025 | $12.8M |
| Jun 2025 | $10.0M |
| Mar 2025 | $5.1M |
| Dec 2024 | $8.1M |
| Sep 2024 | $4.4M |
At each fiscal year end
Single quarter
Net margin, TTM
-23.7%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM SSII
| FY Dec 2025 | -28.5% |
| FY Dec 2024 | -92.7% |
| FY Dec 2023 | -0.4% |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | -19.1% |
| Mar 2026 | -32.3% |
| Dec 2025 | -17.0% |
| Sep 2025 | -29.0% |
| Jun 2025 | -2.6% |
| Mar 2025 | -111.0% |
| Dec 2024 | -23.7% |
| Sep 2024 | -74.0% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$18.4M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM SSII
| FY Dec 2025 | -$22.2M |
| FY Dec 2024 | -$10.2M |
| FY Dec 2023 | -$15.8M |
| FY Dec 2022 | -$6.0M |
| FY Dec 2021 | -$367.0K |
| Jun 2026 | n/a |
| Mar 2026 | -$2.4M |
| Dec 2025 | -$3.2M |
| Sep 2025 | -$8.2M |
| Jun 2025 | -$3.8M |
| Mar 2025 | -$7.0M |
| Dec 2024 | -$3.4M |
| Sep 2024 | -$844.0K |
At each fiscal year end
Single quarter
Debt to equity
0.02x
long-term 2024-06-30 (24 months older than the period end) plus current 2024-03-31 (27 months older than the period end); equity 2026-06-30
Debt to equity SSII
| FY Dec 2025 | 0.03x |
| FY Dec 2024 | 0.08x |
| FY Dec 2023 | 0.03x |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | 0.02x |
| Mar 2026 | 0.02x |
| Dec 2025 | 0.03x |
| Sep 2025 | 0.03x |
| Jun 2025 | 0.03x |
| Mar 2025 | 0.03x |
| Dec 2024 | 0.08x |
| Sep 2024 | 0.08x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-14.57x
TTM operating cash flow over long-term 2024-06-30 (24 months older than the period end) plus current 2024-03-31 (27 months older than the period end)
Cash flow to debt SSII
| FY Dec 2025 | -17.40x |
| FY Dec 2024 | -8.91x |
| FY Dec 2023 | -30.11x |
| FY Dec 2022 | -10.16x |
| FY Dec 2021 | n/a |
| Jun 2026 | -14.57x |
| Mar 2026 | -13.84x |
| Dec 2025 | -17.40x |
| Sep 2025 | -19.03x |
| Jun 2025 | -14.41x |
| Mar 2025 | -12.13x |
| Dec 2024 | -8.91x |
| Sep 2024 | -9.98x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-26.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity SSII
| FY Dec 2025 | -46.9% |
| FY Dec 2024 | -115.5% |
| FY Dec 2023 | -245.1% |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | -26.1% |
| Mar 2026 | -21.1% |
| Dec 2025 | -46.9% |
| Sep 2025 | -43.4% |
| Jun 2025 | -39.1% |
| Mar 2025 | -52.3% |
| Dec 2024 | -115.5% |
| Sep 2024 | -195.4% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-14.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets SSII
| FY Dec 2025 | -20.8% |
| FY Dec 2024 | -51.8% |
| FY Dec 2023 | -108.5% |
| FY Dec 2022 | n/a |
| FY Dec 2021 | -397.7% |
| Jun 2026 | -14.9% |
| Mar 2026 | -13.0% |
| Dec 2025 | -20.8% |
| Sep 2025 | -21.3% |
| Jun 2025 | -21.0% |
| Mar 2025 | -30.4% |
| Dec 2024 | -51.8% |
| Sep 2024 | -87.4% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
Return on invested capital SSII
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
Return on capital employed SSII
| FY Dec 2025 | n/a |
| FY Dec 2024 | -86.1% |
| FY Dec 2023 | -182.2% |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | -27.6% |
| Jun 2025 | -30.6% |
| Mar 2025 | -42.7% |
| Dec 2024 | -86.1% |
| Sep 2024 | -145.8% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing SSII
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$462.3M
market value at close 2026-10-26 on 2026-08-12 shares, plus long-term 2024-06-30 (24 months older than the period end) plus current 2024-03-31 (27 months older than the period end), minus cash 2026-06-30
Enterprise value SSII
| FY Dec 2025 | $1.1B |
| FY Dec 2024 | $1.3B |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | $818.0M |
| Mar 2026 | $986.2M |
| Dec 2025 | $1.1B |
| Sep 2025 | $1.3B |
| Jun 2025 | $1.1B |
| Mar 2025 | $1.9B |
| Dec 2024 | $1.3B |
| Sep 2024 | $683.8M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-3.9%
TTM free cash flow over market value at close 2026-10-26
FCF yield SSII
| FY Dec 2025 | -2.0% |
| FY Dec 2024 | -0.8% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | -2.2% |
| Mar 2026 | -1.8% |
| Dec 2025 | -2.0% |
| Sep 2025 | -1.8% |
| Jun 2025 | -1.3% |
| Mar 2025 | -0.8% |
| Dec 2024 | -0.8% |
| Sep 2024 | -1.7% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing SSII
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $42.5M | $20.6M | $5.9B | $1.4B |
| Gross profit | $19.5M | $8.5M | $725.5K | $60.6K |
| Operating income | -$8.2M | -$19.0M | -$20.3M | -$3.0M |
| Net income | -$12.1M | -$19.2M | -$20.9M | -$3.2M |
| EPS (diluted) | -0.06 | -0.11 | -0.14 | -0.03 |
| Operating cash flow | -$18.5M | -$9.5M | -$15.4M | -$6.0M |
| Cash | $3.2M | $466.5K | $2.0M | $217.2K |
| Long-term debt | n/a | n/a | $510.2K | $469.0K |
SEC XBRL, fiscal years, as known on 2026-10-28
SSII Stock Sonar score 6/7 axes
Find similar shapesCompareSSII ranks highest on growth (93rd percentile) and risk and compliance (87th), and lowest on institutional and government (5th), among Medical Devices peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
SSII filings, in plain words
Are SS Innovations International insiders buying or selling SSII?
In the 180 days to 2026-10-28, SS Innovations International insiders were net sellers, a net $100.0K across purchases and sales reported on Form 4, by 1 seller.
Read the full summary
In the 180 days to 2026-10-28, SS Innovations International insiders were net sellers of SSII, a net $100.0K across purchases and sales reported on Form 4 by 1 seller. Most of that figure, $100.0K, came from a holder of 10% or more rather than an officer or director. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
